Cime Therapeutics

Executive Summary

Cime Therapeutics is a Cambridge-based biotechnology company founded in 2021 that is redefining small molecule drug discovery through a chemistry-first approach. By integrating automation, artificial intelligence, machine learning, and advanced synthetic chemistry, the company aims to overcome key bottlenecks in drug discovery such as speed, purity, and molecular complexity. Its platform is designed to accelerate the creation of novel small molecule therapeutics, addressing a critical need in the pharmaceutical industry for more efficient and effective discovery processes. As a private, early-stage company, Cime Therapeutics is positioned to leverage its innovative platform to build a pipeline of proprietary drug candidates and establish partnerships with larger pharmaceutical firms.

Upcoming Catalysts (preview)

• Q4 2026Series A financing round closure70% success
• 2027First major pharmaceutical partnership or licensing deal50% success
• 2027Announcement of lead candidate entering preclinical development40% success